首页> The journal of pain> Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropathy.

Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropathy.

导出 OA

翻译打印收藏纠错

第一作者： George,Warren

第一单位： Artelo Biosciences Limited, UK.

作者： George,Warren ^[1] ; Myles,Osborn ^[1] ; Christopher,Tsantoulas ^[2] ; Ana,David-Pereira ^[2] ; Daniel,Cohn ^[2] ; Paul,Duffy ^[3] ; Linette,Ruston ^[4] ; Clare,Johnson ^[5] ; Heather,Bradshaw ^[5] ; Martin,Kaczocha ^[6] ; Iwao,Ojima ^[7] ; Andrew,Yates ^[1] ; Saoirse E,O'Sullivan ^[1]

作者单位： Artelo Biosciences Limited, UK. ^[1] Transpharmation Ltd., London, UK. ^[2] Apconix Ltd., UK. ^[3] Seda Pharma Development Services Ltd., UK. ^[4] Department of Psychological and Brain Sciences, Bloomington, Indiana. ^[5] Department of Anesthesiology, Stony Brook University, New York; Institute of Chemical Biology and Drug Discovery, Stony Brook University, New York. ^[6] Department of Chemistry, Stony Brook University, New York; Institute of Chemical Biology and Drug Discovery, Stony Brook University, New York. ^[7]

关键词 Cannabinoid Chemotherapy-induced peripheral neuropathy Fatty acid bind protein Lipid Pain